Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7787 in Advanced Solid Tumors
NCT06605222Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-7787 in solid tumor, sponsored by Hengrui Therapeutics. Started Oct 2024; status: recruiting.
02
Drugs
SHR-7787
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06605222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06605222.